Efferth T, Volm M
German Cancer Research Center, Heidelberg.
Cancer Lett. 1993 Jul 16;70(3):197-202. doi: 10.1016/0304-3835(93)90231-w.
Resistance of tumor cells to doxorubicin is a multifactorial phenomenon. In the present investigation, the ability of resistance modifiers against different resistance mechanisms was analysed. Substances which block P-glycoprotein (P-170) function circumvented resistance of doxorubicin-resistant sarcoma 180 (S180) cells completely (verapamil, thioridazine) or partially (hycanthone), whereas inhibitors of glutathione S-transferase (ethacrynic acid, N-ethylmaleimide, buthionine sulfoximine), and protein kinase C (staurosporine, acridine orange) caused only a partial reversion of resistance. In contrast, an inhibitor of alkaline phosphatase (levamisole) did not overcome doxorubicin-resistance. These results indicate that P-glycoprotein blockers might be more effective to modulate doxorubicin-resistance of S180 cells as compared to other modifiers. Further investigations using other MDR cell lines are required to clarify the generality of these findings.
肿瘤细胞对阿霉素的耐药性是一种多因素现象。在本研究中,分析了耐药修饰剂针对不同耐药机制的能力。阻断P-糖蛋白(P-170)功能的物质可完全(维拉帕米、硫利达嗪)或部分(海恩酮)克服阿霉素耐药性肉瘤180(S180)细胞的耐药性,而谷胱甘肽S-转移酶抑制剂(依他尼酸、N-乙基马来酰胺、丁硫氨酸亚砜胺)和蛋白激酶C抑制剂(星形孢菌素、吖啶橙)仅能部分逆转耐药性。相比之下,碱性磷酸酶抑制剂(左旋咪唑)不能克服阿霉素耐药性。这些结果表明,与其他修饰剂相比,P-糖蛋白阻滞剂可能更有效地调节S180细胞的阿霉素耐药性。需要使用其他多药耐药细胞系进行进一步研究,以阐明这些发现的普遍性。